title: Preclinical and Preliminary Clinical Evaluation of Genetically Transduced Dermal Tissue Implants for the Sustained Secretion of Erythropoietin and Interferon α.
abstract: Protein drugs are currently delivered by bolus injection and although treatment frequently is successful, these methods also have major drawbacks, which call for the development of alternative technologies allowing prolonged delivery of these drugs. We developed a new ex vivo gene therapy platform called Transduced Autologous Restorative Gene Therapy (TARGT) for sustained long term production and secretion of autologous therapeutic proteins. A biopsy of dermal tissue taken from the patient is transduced ex vivo with a viral vector encoding the required gene under a constitutive promoter. Following measurement of protein secretion ex vivo, the transduced dermal tissue is implanted back into the patient, where it secretes the therapeutic protein into the circulation for several months or longer. A major hurdle to this approach is potential immunogenicity of the transduced tissue following implantation. In this paper we describe the preclinical and early clinical development of this technology, which allowed for overcoming these hurdles. To that end, we have used the helper dependent (HD) adenoviral vector with newly designed expression cassette containing genetic elements to optimize transgene expression. Moreover, we have developed procedures for TARGT tissue implantation, with measures to improve engraftment and reduce inflammation and rejection. Implantation of human TARGT to severe combined immune deficient (SCID) mice indicated long-term production of active proteins in the blood. Preliminary results of a clinical trial from two anemic end-stage renal disease patients, implanted with TARGTs expressing the human erythropoietin (EPO) gene, demonstrated prolonged secretion with physiologic blood level of the hormone and hemoglobin maintenance in the desired range, for a period of at least 5 months without exogenous EPO administration. We believe that the TARGT technology has the potential to become a platform for the sustained delivery of therapeutic proteins in various clinical indications.
authors.affiliation: 1 Medgenics Medical Israel, Ltd., Misgav, Israel.
authors.forename: Nir
authors.initials: N
authors.lastname: Shapir
authors.affiliation: 1 Medgenics Medical Israel, Ltd., Misgav, Israel.
authors.forename: Reem
authors.initials: R
authors.lastname: Miari
authors.affiliation: 1 Medgenics Medical Israel, Ltd., Misgav, Israel.
authors.forename: Shany
authors.initials: S
authors.lastname: Blum
authors.affiliation: 2 Nephrology and Dialysis Department, The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
authors.forename: Doron
authors.initials: D
authors.lastname: Schwartz
authors.affiliation: 2 Nephrology and Dialysis Department, The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
authors.forename: Gil
authors.initials: G
authors.lastname: Chernin
authors.affiliation: 3 Medgenics, Inc., Wayne, Pennsylvania.
authors.forename: Garry A
authors.initials: GA
authors.lastname: Neil
authors.affiliation: 1 Medgenics Medical Israel, Ltd., Misgav, Israel.
authors.forename: Daniel
authors.initials: D
authors.lastname: Afik
authors.affiliation: 4 Department of Biochemistry (IMRIC), The Hebrew University-Hadassah Medical School , Jerusalem, Israel .
authors.forename: Amos
authors.initials: A
authors.lastname: Panet
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000328:Adult; D000368:Aged; D000818:Animals; D004921:Erythropoietin / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D016898:Interferon-alpha / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D051437:Renal Insufficiency / Q000628:therapy*; D016038:Skin Transplantation / Q000009:adverse effects / Q000379:methods*
chemical_list: D016898:Interferon-alpha; D004921:Erythropoietin